Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin declines year over year

Q2 FY2026 selling, general & admin of $23.51M fell 9.6% year over year, ahead of the -24.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.7% from the prior quarter. Over 3 fiscal years it compounded at -19.7% a year.

Context

  • Selling, general & admin amounted to 36.0% of revenue in FY2025, down 37.2 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $488.99M (+380.4%) for the fiscal year ending Dec 2026, a step up from the -40.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$23.51M+6.7% QoQ
Last fiscal yearDec 2025
$101.79M-40.8% YoY
LTMJun 2026
$100.97M-24.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.6%+374.3%+384.0 pp
1 year-40.8%+380.4%+421.2 pp
3-year CAGR-19.7%+86.2%+105.9 pp
5-year CAGR+50.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
101.79M USD
Year-over-year change
-40.8%
4-year CAGR
-12.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 selling, general & admin of $100.97M is the 2nd highest of the 10 companies compared; the peer median is $39.39M.
  • Its year-over-year change of -24.6% is the lowest of 9, against a peer median of +25.9%.
  • Selling, general & admin amounts to 32.4% of revenue for AUPH, versus a peer median of 636.8%.
AUPH Competitors Peer median
Selling, General & Admin for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VERAVera Therapeutics, Inc.LTM Jun 2026$153.89M +144.6%+66.0%—
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$100.97M -24.6%-19.7%32.4%
BHVNBiohaven Ltd.LTM Jun 2026$99.69M -4.4%-6.7%—
ALMSAlumis Inc. Common StockLTM Jun 2026$77.08M +17.2%+94.2%1041.9%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$46.46M +34.5%+22.2%—
TRAXFirst Tracks Biotherapeutics IncFY2025$39.39M +37.0%——
EVMNEvommune, Inc.LTM Mar 2026$22.64M ——226.4%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M +5.5%-4.4%269.8%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$16.54M -15.6%+10.2%—
ATTOAttovia Therapeutics, Inc.FY2025$13.55M +83.7%—1003.9%
Peer median (excluding AUPH) $39.39M+25.9%+16.2%636.8%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue45.61M134.03M175.51M235.13M283.06M
Cost of Revenue1.09M5.66M14.15M28.25M32.67M
Gross Profit44.51M128.37M161.37M206.89M250.39M
Gross Margin97.6%95.8%91.9%88.0%88.5%
Research & Development51.14M44.99M49.64M20.79M32.51M
Selling, General & Admin171.44M196.37M195.04M172.03M101.79M
Operating Expenses225.25M239.84M253.06M211.57M145.48M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
EBITDA(177.45M)(103.65M)(63.05M)31.73M127.76M
EBITDA Margin-389.1%-77.3%-35.9%13.5%45.1%
Operating Income(180.74M)(111.47M)(91.69M)(4.69M)104.91M
Operating Margin-396.3%-83.2%-52.2%-2.0%37.1%
Interest Income529K5.12M17M16.97M13.57M
Interest Expense002.78M4.84M4.33M
Other Income / Expenses529K5.12M14.22M12.14M9.24M
Income Before Tax(180.21M)(106.35M)(77.47M)7.45M114.16M
Pre-Tax Margin-395.1%-79.3%-44.1%3.2%40.3%
Income Tax Expense760K1.83M551K1.7M(173.05M)
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Net Margin-396.8%-80.7%-44.5%2.4%101.5%
EPS (Basic)(1.40)(0.76)(0.54)0.042.14
EPS (Diluted)(1.40)(0.76)(0.54)0.042.07
Weighted Avg Shares129.37M141.92M143.24M143.06M134.37M
Weighted Avg Shares (Diluted)129.37M141.92M143.24M146.19M138.7M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.